“We are excited to be building an open source community around the cBioPortal, and The Hyve has become an integral part of our efforts. The Hyve brings unique expertise in building open source bioinformatics platforms, and in building bridges between academic centers and industry, and we look forward to continued work together.”Ethan Cerami, PhDDirector, Knowledge Systems Group
Department of Biostatistics and Computational Biology Dana-Farber Cancer Institute

"We use the RADAR-base platform in combination with various wearables as an instrument for continuous monitoring of subjects in early phase drug trials. It enables us to reliably monitor pharmacodynamics in an at home setting, which minimizes the burden for subjects.”

Ghobad Maleki Clinical Scientist
Centre for Human Drug Research

“Using the highly scalable RADAR-base platform in several European research projects such as IMI RADAR-CNS, IMI RADAR-AD and IMI BigData@Heart, we continuously collect high frequency streaming data from multiple sources. We leverage this data to identify medical relevant signals and pave the way for new digital biomarkers in a variety of medical areas.”

Richard Dobson Professor of Medical Informatics
NIHR Biomedical Research Center, KCL &
Health Data research UK (HDR UK), IHI, UCL

“Over the past years, The Hyve has constituted many important new features to cBioPortal, and their quality has always exceeded our expectations. We look forward to collaborating more and are excited to have them as a partner that can help us build bridges to pharmaceutical companies and other academic centers.” Nikolaus Schultz, PhDHead of Knowledge Systems, Marie-Josée & Henry R. Kravis Center for Molecular OncologyMemorial Sloan Kettering Cancer Center

"A few years ago, we decided to invest in I2B2-tranSMART & Glowing bear as our institute-wide registry for patients and samples and make that data available to all researchers within our institute. We pursued this avenue together with The Hyve and they have been a tremendous help in developing new features, thinking about possible solutions and maintaining the platform."

Patrick KemmerenPrincipal Investigator
Prinses Máxima Center for Pediatric Oncology